training module for medical officers primary health centre - NVBDCP

More documents

Recommendations

Info

National Drug Policy, 2008Treatment of Plasmodium vivax casesMicroscopically positive Plasmodium vivax cases should be treated with chloroquine in full therapeuticdose of 25 mg/kg body weight divided over three days (10 + 10 + 5 mg/Kg body weight on days 1, 2 and3 respectively). Primaquine should be given in dose of 0.25mg/kg body weight daily for 14 days toprevent relapse.Table 7.1 Chloroquine dosage schedule for P. vivax casesAge in yearsDay – 1(10mg/Kg)Day – 2(10mg/Kg)Day – 3(5 mg/Kg) 30%) and approval of Directorate of NVBDCP. Resistance should also besuspected if in spite of full treatment with no history of vomiting, diarrhea, patient does not respond33
within 72 hours of treatment. Such individual patients should be given alternative drug i.e. ACTcombination and report to concerned District Malaria / State Malaria Officer/ROHFW Pf monitoringteams for monitoring of drug sensitivity status.ACT should be given only to confirmed P. falciparum cases found positive by microscopy or RapidDiagnostic kits. The dose is 4mg/kg body weight of Artesunate (AS) daily for 3 days, combined with25mg/ kg body weight of sulphadoxine/sulphalene + 1.25 mg per kg body weight of pyrimethamine(SP) on the first day. Artesunate tablets should not be administered as mono therapy. It shouldinvariably be combined with sulpha pyrimethamine tablets in prescribed dosages. Strength of eachArtesunate tablet: is 50 mg and each Sulpha Pyrimethamine (SP) tablet contain 500mgsulphadoxine/sulphalene and 25mg pyrimethamineACT Dosage Schedule for Plasmodium falciparum cases * - 3 DaysAge1 st Day(Number of tabs)*2 nd Day(Number of tabs)3 rd Day(Numbers of tabs)< 1 year ASSP1 - 4 years ASSP5 - 8 years ASSP9 - 14 years ASSP15 years and ASabove SP½¼1121 ½3243½Nil1Nil2Nil3Nil4Nil½Nil1Nil2Nil3Nil4NilAS- ArtesunateSP- Sulpha-PyrimethamineA single dose of Primaquine i.e. 0.75 mg/kg body weight, is recommended to be given with ACTcombination as it will enhance gametocyte clearance and facilitate interruption of transmission.Primaquine should also be not used in pregnant women and infants. As per current National PolicyArtemisinin derivatives are not to be used in pregnant women.As per the current National policy, in all states not mentioned above and in areas not known to havechloroquine resistance, microscopically positive Pf cases should be treated with chloroquine intherapeutic dose of 25 mg/kg body weight divided over three days (similar to P. vivax cases) and asingle dose of Primaquine 0.75 mg/kg body weight on the first day.34
Page 1 and 2: TRAINING MODULEFORMEDICAL OFFICERSP
Page 3 and 4: Distribution of malariaSESSION - 1:
Page 5 and 6: National Malaria Eradication Progra
Page 7 and 8: 1.2 : JOB RESPONSIBILITIES OF MO- P
Page 9 and 10: SESSION - 2: MALARIOLOGY2.1: EPIDEM
Page 11 and 12: 2.2: MORPHOLOGY, LIFE CYCLE AND TRA
Page 13 and 14: Table 2.1: Differentiation of chara
Page 15 and 16: 2.3: VECTOR MOSQUITOES AND THEIR BI
Page 17 and 18: Bionomics of vector species in Indi
Page 19 and 20: 2.4: EPIDEMIOLOGICAL AND ENTOMOLOGI
Page 21 and 22: Entomological parameters should be
Page 23 and 24: Cerebrospinal fluid (CSF) is clear
Page 25 and 26: 3.2: LABORATORY DIAGNOSIS OF MALARI
Page 27 and 28: Examination of blood films for mala
Page 29 and 30: Plate 1: Plasmodium falciparum thin
Page 31 and 32: 3.3: MALARIA CASE MANAGEMENTAntimal
Page 33: This ACT is highly effective agains
Page 37 and 38: In pregnancy, malaria, especially P
Page 39 and 40: Advice to the patients / caretakers
Page 41 and 42: The choice between IRS and ITN/LLIN
Page 43 and 44: Deploy staff for active case detect
Page 45 and 46: Visit the PHCs, subcenters and vill
Page 47 and 48: The Rapid Diagnosis Test (RDT) is d
Page 49 and 50: It should also be ensured that the
Page 51 and 52: Common problems for reluctance to g
Page 53 and 54: 3. Programme management Monitoring
Page 55 and 56: Worker (SFW) to the PHC-MO where a
Page 57 and 58: The data collected through the syst
Page 59 and 60: Outcome - IRS Coverage - Population
Page 61 and 62: Level Staff FrequencySupervisor (wh
Page 63 and 64: With improved access to quality cas
Page 65 and 66: If an epidemic is predominantly due
Page 67 and 68: 500@ 20-25 houses per pump per day
Page 69 and 70: 3.1.6 Name of Laboratory Technician
Page 71 and 72: 3. Therefore, unless the deceased h
Page 73 and 74: To accord priority for IRS in areas
Page 75 and 76: Consumption of insecticide as deter
Page 77 and 78: Step 9: Wash equipments (basin, mea
Page 79 and 80: ProgramComponentBed netimpregnation
Page 81 and 82: Benefit of indoor insecticidal spra
Page 83 and 84: The MO-PHC is expected to provide a
Page 85 and 86:
Ensure that they have adequate supp
Page 87 and 88:
4.8: LOGISTICS MANAGEMENTPlanningPl
Page 89 and 90:
Planning of LLIN coverage is compli
Page 91 and 92:
communication among the community f
Page 93 and 94:
Examine level of stocksLook for unr
Page 95 and 96:
During planned bednet distribution
Page 97:
How many of the individuals actuall
show all

training module for medical officers primary health centre - NVBDCP

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?